Repligen
RGEN
$165.88
Share price
3.46%
Change (1 day)
-14.02%
Change (1 year)
Revenue for Repligen (RGEN)
Revenue in 2022 (TTM): $0.73 B
According to Repligen 's latest financial reports the company's current revenue (TTM) is $0.73 B. In 2021 the company made a revenue of $0.67 B an increase over the years 2020 revenue that were of $0.36 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Repligen from 2001 to 2022
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2022 (TTM) | $0.73 B | 9.48% |
| 2021 | $0.67 B | 83.08% |
| 2020 | $0.36 B | 35.53% |
| 2019 | $0.27 B | 39.28% |
| 2018 | $0.19 B | 37.38% |
| 2017 | $0.14 B | 35.1% |
| 2016 | $0.10 B | 25.14% |
| 2015 | $0.08 B | 31.45% |
| 2014 | $0.06 B | -6.78% |
| 2013 | $0.06 B | 9.48% |
| 2012 | $0.06 B | |
| 2010 | $0.02 B | 26.89% |
| 2009 | $0.02 B | -26.28% |
| 2008 | $0.02 B | 42.52% |
| 2007 | $0.01 B | 48.52% |
| 2006 | $0.01 B | 1.84% |
| 2005 | $0.01 B | 53.56% |
| 2004 | $8.47 M | 23.81% |
| 2003 | $6.84 M | -5.49% |
| 2002 | $7.24 M | 99.57% |
| 2001 | $3.63 M |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $92.36 B | 12,482.40% | 🇺🇸 USA |
 Thermo Fisher Scientific TMO | $41.12 B | 5,501.85% | 🇺🇸 USA |
 General Electric GE | $74.11 B | 9,996.49% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $46.46 B | 6,229.68% | 🇺🇸 USA |
 Sangamo Therapeutics
SGMO | $0.11 B | -84.65% | 🇺🇸 USA |
 Novavax NVAX | $1.30 B | 77.60% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | $1.20 B | 64.49% | 🇺🇸 USA |
 Bio-Techne TECH | $1.07 B | 46.63% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | $1.87 B | 156.04% | 🇺🇸 USA |
 Charles River Laboratories
CRL | $3.62 B | 394.42% | 🇺🇸 USA |